Spectrum Pharmaceuticals files INDA for cancer drug
Spectrum says the drug, SPI-1620, is a highly selective endothelin-B agonist that has demonstrated in experimental models a transient and selective increase in blood flow to tumors by
Spectrum says the drug, SPI-1620, is a highly selective endothelin-B agonist that has demonstrated in experimental models a transient and selective increase in blood flow to tumors by
The inhaler, which is GSK’s top-selling product, is used for treating COPD, a lung disease comprised of chronic bronchitis and emphysema. The approval was granted following a regulatory
The results of both randomized, double-blind, placebo-controlled studies, one in common obesity and the other in morbid obesity, demonstrated no statistically or clinically meaningful placebo adjusted weight loss
Actemra successfully met its primary endpoint in patients with moderate to severe rheumatoid arthritis (RA) who failed to respond to anti-tumor necrosis factor treatments (anti-TNFs). The trial –
The worldwide exclusive license deal includes an upfront fee and milestone payments as well as royalties on future sales. A novel drug technology to treat Alzheimer’s disease developed
Suffers of mesothelioma, a lung cancer linked with asbestos exposure, have welcomed the government’s U-turn. The National Institute for Health and Clinical Excellence (Nice) reversed its decision after
As such, DCVax-Brain is the first commercially available therapeutic vaccine for such cancers, according to Biotherapeutics, which intends to begin making the product available to patients in Q3
Rivaroxaban achieved superior efficacy in the prevention of venous thromboembolism (VTE) in patients undergoing knee replacement surgery in a head-to-head comparison with Sanofi-Aventis’ Lovenox, known generically as enoxaparin,
Top-line data from the first of two phase III clinical studies to assess the safety and efficacy of tolevamer liquid, a polymer therapy for patients with Clostridium difficile
In the randomized, six week, placebo-controlled trials involving a total of 1,551 subjects, PreHistin did not achieve statistically significant differences from placebo in the primary measure of efficacy,